Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085806 | 0.97 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20085803 | 0.94 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20112884 | 0.82 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20112984 | 0.79 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20085810 | 0.76 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL22342084 | 0.73 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20088867 | 0.72 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20085804 | 0.71 | KDM4E (0.44) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20085805 | 0.71 | HPGD (0.48) | ALDH1A1MAPT | |
| SCHEMBL20085800 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109890823-B | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| US-10155769-B2 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| WO-2018080916-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155769-B2 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | NPC1 1690/4885RAB9A 2642/4885SMN1; SMN2 2072/4885 |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | NPC1 1690/4885RAB9A 2642/4885SMN1; SMN2 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.